Compared with the CRP/Alb ratio ≤0.089 group, the CRP/Alb ratio >0.089 group comprised significantly more patients with tumor size >5 cm (50% vs. 21.4%, p = 0.019) and bile duct tumor invasion (65.4% vs. 39.3%, p = 0.034). This evidence concerns the gene ALB and neoplasm.